


Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Dec-2023
Document Type: USP Monographs
DocId: GUID-52C2BB50-40D9-4F65-A6D5-19BF38199E26_3_en-US
DOI: https://doi.org/10.31003/USPNF_M52780_03_01
DOI Ref: 3p4lz

© 2025 USPC
Do not distribute

Methylprednisolone

Change to read:



$C_{22}H_{30}O_5$ ▲374.48▲ (USP 1-Dec-2023)
Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6 α ,11 β)-;
11 β ,17,21-Trihydroxy-6 α -methylpregna-1,4-diene-3,20-dione CAS RN®: 83-43-2; UNII: X4W7ZR7023.

DEFINITION
Methylprednisolone contains NLT 97.0% and NMT 103.0% of methylprednisolone ($C_{22}H_{30}O_5$), calculated on the dried basis.

IDENTIFICATION

Change to read:

• **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197K▲ or 197A▲ (USP 1-Dec-2023)

Delete the following:

▲ **B. SPECTROSCOPIC IDENTIFICATION TESTS (197), Ultraviolet-Visible Spectroscopy:**▲ (USP 1-Dec-2023)

Add the following:

▲ **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-Dec-2023)

Delete the following:

▲ **C.**▲ (USP 1-Dec-2023)

ASSAY

Change to read:

• **PROCEDURE**

▲ **Solution A:** [Acetonitrile](#), [tetrahydrofuran](#), [phosphoric acid](#), and [water](#) (10: 1.5: 0.1: 90)

Solution B: [Acetonitrile](#), [tetrahydrofuran](#), and [phosphoric acid](#) (100: 1.5: 0.1)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	83	17
14	83	17
30	52	48
30.1	83	17
35	83	17

Diluent: [Acetonitrile](#), [phosphoric acid](#), and [water](#) (50: 0.1: 50)

System suitability solution: 0.6 mg/mL of [USP Methylprednisolone System Suitability Mixture RS](#) in *Diluent*
Standard solution: 0.6 mg/mL of [USP Methylprednisolone RS](#) in *Diluent*
Sample solution: 0.6 mg/mL of Methylprednisolone in *Diluent*

Chromatographic system
(See [Chromatography \(621\), System Suitability](#).)
Mode: LC
Detector: UV 247 nm
Column: 4.6-mm × 15-cm; 3-μm packing [L1](#)
Column temperature: 45°
Flow rate: 1.5 mL/min
Injection volume: 10 μL

System suitability
Sample: *System suitability solution* and *Standard solution*
[NOTE—The relative retention times for methylprednisolone related compound A and methylprednisolone are 0.93 and 1.0, respectively.]
Suitability requirements
Resolution: NLT 1.7 between methylprednisolone related compound A and methylprednisolone, *System suitability solution*
Relative standard deviation: NMT 1.10%, *Standard solution*

Analysis
Samples: *Standard solution* and *Sample solution*
Calculate the percentage of methylprednisolone ($C_{22}H_{30}O_5$) in the portion of Methylprednisolone taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of methylprednisolone from the *Sample solution*
 r_S = peak response of methylprednisolone from the *Standard solution*
 C_S = concentration of [USP Methylprednisolone RS](#) in the *Standard solution* (mg/mL)
 C_U = concentration of Methylprednisolone in the *Sample solution* (mg/mL)▲ (USP 1-Dec-2023)

Acceptance criteria: 97.0%–103.0% on the dried basis

IMPURITIES
• [RESIDUE ON IGNITION \(281\)](#): NMT 0.2%
Change to read:
• **ORGANIC IMPURITIES**

▲**Solution A, Solution B, Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system:** Proceed as directed in the Assay.
Sensitivity solution: 0.0003 mg/mL of [USP Methylprednisolone RS](#) in *Diluent*
Standard solution: 0.006 mg/mL of [USP Methylprednisolone RS](#) in *Diluent*
System suitability
Samples: *System suitability solution, Sensitivity solution, and Standard solution*

[NOTE—See [Table 2](#) for the relative retention times. The relative retention times in [Table 2](#) are provided for information that could aid in peak assignment.]

Table 2

Name	Relative Retention Time
Methylprednisolone related compound B	0.85
Methylprednisolone related compound H	0.88
Methylprednisolone related compound A	0.93
Methylprednisolone	1.0
Methylprednisolone related compound F	1.10
Methylprednisolone related compound G	1.56
Impurity I	1.60
Methylprednisolone related compound C	1.72

Name	Relative Retention Time
Methylprednisolone related compound E	2.01
Methylprednisolone related compound D (trans isomer)	2.21
Methylprednisolone related compound D (cis isomer)	2.34

Suitability requirements

Resolution: NLT 1.7 between methylprednisolone and methylprednisolone related compound A, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Sample solution* and *Standard solution*

Calculate the percentage of each impurity in the portion of Methylprednisolone taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of methylprednisolone from the *Standard solution*

C_S = concentration of [USP Methylprednisolone RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Methylprednisolone in the *Sample solution* (mg/mL)

F = relative response factor (see [Table 3](#))

Acceptance criteria: See [Table 3](#). The reporting threshold is 0.05%.

Table 3

Name	Relative Response Factor	Acceptance Criteria, NMT (%)
Methylprednisolone related compound B	1.0	0.2
Methylprednisolone related compound H	1.0	0.2
Methylprednisolone related compound A	1.0	0.3
Methylprednisolone related compound F	1.0	0.15
Sum of methylprednisolone related compound G and Impurity I	1.0	0.3
Methylprednisolone related compound C	1.2	0.15
Methylprednisolone related compound E	1.0	0.15
Methylprednisolone related compound D ^a	1.0	0.5
Any unspecified impurity	1.0	0.10
Total impurities	—	2.0

^a Sum of trans isomer and cis isomer.

▲ (USP 1-Dec-2023)

SPECIFIC TESTS

Change to read:

- **OPTICAL ROTATION (781S), Procedures, Specific Rotation**

Sample solution: ▲10 mg/mL in [alcohol](#)▲ (USP 1-Dec-2023)

Acceptance criteria: ▲+97.0° to +103.0°, calculated on the dried basis ▲ (USP 1-Dec-2023)

- [Loss on Drying \(731\)](#).

Analysis: Dry at 105° for 3 h.

Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. ▲Store at controlled cold temperature. ▲ (USP 1-Dec-2023)

Change to read:

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Methylprednisolone RS](#)

▲ [USP Methylprednisolone System Suitability Mixture RS](#)

Contains a mixture of the following 10 compounds:

Methylprednisolone.

Methylprednisolone related compound A: 17,21-Dihydroxy-6α-methylpregna-1,4-diene-3,11,20-trione.



Methylprednisolone related compound B: 11β,17,21,21-Tetrahydroxy-6α-methylpregna-1,4-diene-3,20-dione.



Methylprednisolone related compound C: 11β-Hydroxy-6α-methylandrosta-1,4-diene-3,17-dione.



Methylprednisolone related compound D: 11β,20-Dihydroxy-6α-methylpregna-1,4,17(20)-triene-3,21-dione.



Methylprednisolone related compound E: 11β-Hydroxy-6α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylic acid.



Methylprednisolone related compound F: 11β,17,21-Trihydroxy-6α-methylpregn-4-ene-3,20-dione.



Methylprednisolone related compound G: 17,21-Dihydroxy-6α-methylpregna-1,4,9(11)-triene-3,20-dione.



Methylprednisolone related compound H: 11β,17,21-Trihydroxy-6β-methylpregna-1,4-diene-3,20-dione.



Impurity I: Unknown structure.

▲ (USP 1-Dec-2023)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METHYLPREDNISOLONE	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 48(4)

Current DocID: GUID-52C2BB50-40D9-4F65-A6D5-19BF38199E26_3_en-US

DOI: https://doi.org/10.31003/USPNF_M52780_03_01

DOI ref: [3p4lz](#)